News

From February 10 to 13, Autobio made a notable appearance at WHX Labs Dubai 2026, the preeminent laboratory equipment exposition in the Middle East, held at the Dubai World Trade Centre. Autobio's comprehensive solutions of cutting-edge in vitro diagnostic (IVD) products and expertly executed trade show activities garnered significant international attention, showcasing the formidable prowess of Chinese intelligent manufacturing within the global medical sector.

At the exhibition, Autobio presented a comprehensive portfolio of products encompassing major IVD fields. These included a fully automated chemiluminescence immunoassay analyzer, the AutoLumo S900, along with supporting reagents for tuberculosis, allergies, infectious diseases, and other areas of immunodiagnostics. The company also showcased a total microbiology laboratory solution, the BC120Plus blood culture system, and the Autof TX8 microbial mass spectrometry system for microbiological testing. Additionally, Autobio highlighted a high-performance, fully automated coagulation analyzer for coagulation testing and the Sikun series gene sequencers for the NGS field. The diversified product layout fully reflected Autobio's strong technical strength and full-scenario solution capabilities in the IVD industry.

The Autobio booth experienced a high volume of activity during the exhibition. A high volume of international visitors arrived to inquire about product performance, application scenarios, and technical innovations. Autobio's professional international team provided detailed demonstrations and in-depth explanations for the visitors, and conducted face-to-face in-depth communication with domestic and foreign customers, accurately capturing market demands and laying a solid foundation for in-depth global cooperation and market expansion. The exceptional performance of Autobio's products and professional services received unanimous praise and high recognition from the audience and industry peers.

As a leading company in China's IVD industry, Autobio has always adhered to an innovation-driven development strategy and deepened the global layout of "globalization integration with localization." Autobio's participation in WHX Labs Dubai 2026 is a testament to its technological competitiveness and product innovation strength. This presence also fosters international exchanges and cooperation in the medical industry, contributing to the advancement of medical technology and innovation. Autobio plans to maintain its commitment to IVD technology R&D and product iteration. The company will also enhance its global service system and collaborate with international partners to contribute to the advancement of precision medical care and human health on a global scale.